PATENT CLAIM ANALYSIS

Application Number: 15779611
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "327000"]

Abstract:
The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.

Claim (Index 26):
A method of treating an infectious disease comprising administering to a subject the pharmaceutical composition for intravenous administration comprising a hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl]phenyl)-N\u2032-(3-fluoro-2-methylphenyl)urea and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical acceptable excipient is selected from the group consisting of sulfobutyl ether-\u03b2-cyclodextrin (Captisol\u00ae), mannitol, and a citrate buffer.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.39394
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14668683', '10553139', '13704145', '12370794', '16073580']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.702099530254308
- 35 USC 102 Novelty (BERT): 0.4797179685065593
- Combined Prediction Score: 0.6798613740795332
- Mean Citation Score: 172.468098
- Max Citation Score: 174.8063
- Similarity Product: 133.52370380036828

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test